W
Wenrui Wang
Researcher at Bengbu Medical College
Publications - 26
Citations - 492
Wenrui Wang is an academic researcher from Bengbu Medical College. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 9, co-authored 20 publications receiving 285 citations.
Papers
More filters
Journal ArticleDOI
Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer.
Wenrui Wang,Tiantian Chen,Henan Xu,Baihui Ren,Xiaodan Cheng,Rongrong Qi,Haibo Liu,Yueyue Wang,Lei Yan,Sulian Chen,Qingling Yang,Changjie Chen +11 more
TL;DR: The results suggested that Cur-SLNs could be a potential useful chemotherapeutic formulation for breast cancer therapy.
Journal ArticleDOI
Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Wenrui Wang,Lingyu Zhang,Yangyang Wang,Yongxing Ding,Tiantian Chen,Yueyue Wang,Haifeng Wang,Yu Li,Kecai Duan,Sulian Chen,Qingling Yang,Changjie Chen +11 more
TL;DR: It is shown that miR-451 is decreased in human breast cancer specimens and in paclitaxel-resistant (PR) cells, and the results of xenograft model in vivo showed that intratumor injection of miR -451 agomir induced a tumor-suppressive effect in SKBR3/PR drug-resistant xenografted model.
Journal ArticleDOI
Anticancer Effects of Resveratrol-Loaded Solid Lipid Nanoparticles on Human Breast Cancer Cells
Wenrui Wang,Lingyu Zhang,Tiantian Chen,Wen Guo,Xunxia Bao,Dandan Wang,Baihui Ren,Haifeng Wang,Yu Li,Yueyue Wang,Sulian Chen,Baoding Tang,Qingling Yang,Changjie Chen +13 more
TL;DR: Results indicate that the resveratrol-loaded solid lipid nanoparticles (Res-SLN) may have great potential for breast cancer treatment.
Journal ArticleDOI
Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells.
Yueyue Wang,Lei Yan,Shuo Yang,Henan Xu,Tiantian Chen,Zheng‐Yuan Dong,Sulian Chen,Wenrui Wang,Qingling Yang,Changjie Chen +9 more
TL;DR: Results suggest that AC073284.4 might function as a potential novel diagnostic biomarker in the progression of BC through modulating miR‐18b‐5p/DOCK4 axis, which weakens EMT and migration of BC.
Journal ArticleDOI
Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells
Lei Yan,Shuo Yang,Cheng‐Xu Yue,Xin‐Yu Wei,Wei Peng,Zheng‐Yuan Dong,Henan Xu,Sulian Chen,Wenrui Wang,Changjie Chen,Qingling Yang +10 more
TL;DR: H19 could act as a ceRNA in BC progression, metastasis and EMT through modulating miR-340-3p/YWHAZ axis and activating the canonical Wnt/β-catenin signaling pathway, indicating that H19 might act as an underlying therapeutic target and prognostic biomarker for BC therapy.